Search results
Results from the WOW.Com Content Network
[[Category:Medication templates]] to the <includeonly> section at the bottom of that page. Otherwise, add <noinclude>[[Category:Medication templates]]</noinclude> to the end of the template code, making sure it starts on the same line as the code's last character.
A retrospective analysis of five million patient records with the US Department of Veterans Affairs system found different types of commonly used antihypertensive medications had very different AD outcomes. Those patients taking angiotensin receptor blockers (ARBs) were 35 to 40% less likely to develop AD than those using other antihypertensives.
[[Category:Drug templates by ATC]] to the <includeonly> section at the bottom of that page. Otherwise, add <noinclude>[[Category:Drug templates by ATC]]</noinclude> to the end of the template code, making sure it starts on the same line as the code's last character.
Medication Major brand names Form Dosage Oral: Testosterone a – Tablet: 400–800 mg/day (in divided doses) Testosterone undecanoate: Andriol, Jatenzo: Capsule: 40–80 mg/2–4× day (with meals) Methyltestosterone b: Android, Metandren, Testred: Tablet: 10–50 mg/day Fluoxymesterone b: Halotestin, Ora-Testryl, Ultandren: Tablet: 5–20 mg ...
[[Category:Medicine templates]] to the <includeonly> section at the bottom of that page. Otherwise, add <noinclude>[[Category:Medicine templates]]</noinclude> to the end of the template code, making sure it starts on the same line as the code's last character.
Main page; Contents; Current events; Random article; About Wikipedia; Contact us; Pages for logged out editors learn more
Lucinactant (trade name Surfaxin) is a liquid medication used to treat infant respiratory distress syndrome. [1] It is a pulmonary surfactant for infants who lack enough natural surfactant in their lungs.
Template:Medications and dosages used in hormone therapy for transgender men References ^ Hembree WC, Cohen-Kettenis PT, Gooren L, Hannema SE, Meyer WJ, Murad MH, Rosenthal SM, Safer JD, Tangpricha V, T'Sjoen GG (November 2017).